A Randomized, Double-blind Placebo-controlled Study of the Maintenance of Efficacy of Etanercept Plus Dmard(s) Compared With Dmard(s) Alone in Subjects With Rheumatoid Arthritis After Achieving an Adequate Response With Etanercept Plus Dmard(s)

Trial Profile

A Randomized, Double-blind Placebo-controlled Study of the Maintenance of Efficacy of Etanercept Plus Dmard(s) Compared With Dmard(s) Alone in Subjects With Rheumatoid Arthritis After Achieving an Adequate Response With Etanercept Plus Dmard(s)

Completed
Phase of Trial: Phase IV

Latest Information Update: 08 Nov 2017

At a glance

  • Drugs Etanercept (Primary) ; Disease-modifying antirheumatics; Methotrexate
  • Indications Rheumatoid arthritis
  • Focus Therapeutic Use
  • Sponsors Pfizer
  • Most Recent Events

    • 08 Nov 2017 Results of post hoc analysis from 3 etanercept study (NCT01578850, NCT00565409 and NCT00913458) presented at the 81st American College of Rheumatology and the 52nd Association of Rheumatology Health Professionals Annual Scientific Meeting
    • 10 Jun 2017 Biomarkers information updated
    • 20 May 2015 Status changed from active, no longer recruiting to completed as per ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top